The influence of cross-regional medical treatment on total medical expenses, medical insurance payments, and out-of-pocket expenses of patients with malignant tumors in Chinese low-income areas

Bokai Zhang, Haixin Wang, Hongyu Zhang, Guomei Tian, Ting Zhang, Qi Shi, Jian Liu, Jinpeng Xu, Jingchu Liu, Qunhong Wu, Zheng KangCost 2022 · DOI

Abstract

The number of cross-regional medical patients with malignant tumors in low-income areas is affected by seasonal factors, meanwhile, their total medical expenses, actual medical insurance payment levels, and out-of-pocket expenses are all affected by the economic level and geographical distance of medical regions. And the middle-distance medical regions may be the best choice for patients with planned cross-regional medical treatment. These provide some evidence for policymakers to improve the fairness and sustainability of medical security for cross-regional medical patients and reduce their direct economic burden of disease.

Introduction

In China, medical insurance is largely managed at the provincial level. When patients from low-income provinces seek treatment elsewhere—a practice known as cross-regional medical treatment—they often face a "double whammy": higher medical prices in developed regions and reduced reimbursement rates from their home province's insurance fund. This study investigates the "financial toxicity" of medical migration, specifically focusing on patients with malignant tumors from Heilongjiang, an underdeveloped province in Northeast China with a high cancer burden and significant population outflow.

Datasets and Context

The study analyzed 54,904 valid records of cross-provincial direct settlement for medical expenses sourced from the Heilongjiang Medical Security Service Center for the year 2020. Heilongjiang represents a critical case study as it ranks second to last in per capita GDP in China and experiences high rates of medical migration.

Overall situation of cross-provincial medical patients in Heilongjiang (2018-2020)

As shown in Figure 1, the total number of cross-provincial medical patients has grown steadily, with patients suffering from malignant tumors representing a significant and increasing proportion of this population.

Methodology

The researchers employed a retrospective cross-sectional design using a robust statistical toolkit:

  • Spatio-temporal Analysis: Using Microsoft Excel 2019 and ArcGIS 10.2 to map patient migration and temporal trends.
  • Logistic Regression: Binary and multivariate logistic regression models were used to calculate Adjusted Odds Ratios (AOR), isolating the impact of destination economics and distance while controlling for variables like age and insurance type.
  • Sensitivity Analysis: Models were validated by adding "length of stay" as a variable and focusing specifically on lung cancer patients.

Key Insights and Results

Patient numbers follow a distinct "U-shaped" seasonal trend. There is a sharp dip in January and February (coinciding with the Chinese Spring Festival) and a peak in December. The harsh winter and poor air quality in Northeast China may drive cancer patients to seek care elsewhere late in the year.

Monthly statistics of cross-provincial medical patients with malignant tumors in 2020

Figure 2 illustrates that while patient volume fluctuates seasonally, average medical expenses and insurance payments remain relatively stable throughout the year, though they peak slightly in the final months.

The "Wealth Trap" and Proximity Paradox

  • Economic Impact: Patients are drawn to high-economic regions (like Beijing and Shanghai) for superior technology. However, these patients were nearly 3 times more likely to incur high total medical expenses (AOR = 2.932) and over 3.6 times more likely to face high out-of-pocket (OOP) costs compared to those in low-economic regions. This is often due to the use of expensive, innovative drugs not fully covered by home insurance.
  • Distance Impact: While most patients prefer short-distance travel, the study found that middle-distance regions offered the lowest risk of high OOP expenses (AOR = 0.545). Conversely, short-distance regions were associated with a much higher likelihood of lower insurance payment levels (AOR = 5.976).
  • Demographics: Non-elderly patients (<60 years old) were more likely to incur high OOP expenses, likely due to opting for more aggressive, expensive treatments.

Policy Implications and Limitations

The study highlights that current "direct settlement" policies do not necessarily ensure affordability. Local protectionism often leads home provinces to reduce reimbursement ratios for "planned" out-of-province care to discourage the outflow of insurance funds.

Limitations: The database lacked detailed clinical information (e.g., cancer stage), and the cross-sectional nature of the 2020 data prevents establishing definitive causal relationships over time. Future research should utilize panel data and more granular patient information to refine these models and help policymakers improve the fairness of medical security.

Summary updated

Abstract

The number of cross-regional medical patients with malignant tumors in low-income areas is affected by seasonal factors, meanwhile, their total medical expenses, actual medical insurance payment levels, and out-of-pocket expenses are all affected by the economic level and geographical distance of medical regions. And the middle-distance medical regions may be the best choice for patients with planned cross-regional medical treatment. These provide some evidence for policymakers to improve the fairness and sustainability of medical security for cross-regional medical patients and reduce their direct economic burden of disease.
BibTeX
@inproceedings{zhang2022influence,
  author = {Bokai Zhang and Haixin Wang and Hongyu Zhang and Guomei Tian and Ting Zhang and Qi Shi and Jian Liu and Jinpeng Xu and Jingchu Liu and Qunhong Wu and Zheng Kang},
  title = {{The influence of cross-regional medical treatment on total medical expenses, medical insurance payments, and out-of-pocket expenses of patients with malignant tumors in Chinese low-income areas}},
  booktitle = {Cost},
  year = {2022},
  doi = {10.1186/s12962-022-00368-x},
}
Figure